Alzheimer's Disease Acitretin Medication

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The trials investigates the changes of cerebral spinal fluid (CSF) soluble alpha-secretase cleaved APP (APPsα) levels under oral therapy with acitretin 30mg daily in patients with mild to moderate Alzheimer's disease (AD).The present study aims to demonstrate an enhancement of the α-secretase activity by acitretin as measured by increased CSF APPSα levels in human AD. Second, the safety and tolerability of acitretin in AD patients should be proven.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johannes Gutenberg University Mainz; K. Lieb
• Collaborator: Alzheimer Forschungsinitiative e.V. (AFI)
• Treatments: Acitretin

Criteria

Inclusion Criteria:

• mild to moderate AD (NINCDS-ADRDA criteria)

• Mini-Mental State Examination (MMSE): 27-14 points

• Geriatric Depression Scale ≤ 14

Exclusion Criteria:

• hereditary cognitive impairment

• known history of brain injuries

• Insufficient German language skills

• actual treatment with other potential disease modifying drugs of AD

• multimorbidity or significant organ (esp. liver or renal) dysfunction

• evidence of Non-AD neurodegenerative disorder (e.g. Parkinson)

• contraindication to acitretin such as osteoporosis, hypoalbuminaemia